Nalazite se na CroRIS probnoj okolini. Ovdje evidentirani podaci neće biti pohranjeni u Informacijskom sustavu znanosti RH. Ako je ovo greška, CroRIS produkcijskoj okolini moguće je pristupi putem poveznice www.croris.hr
izvor podataka: crosbi !

Botulinum Toxin Type A and Rat Trigeminal Regions: The Search for Mechanism of Antinociceptive Action in Migraine and Other Headaches (CROSBI ID 634117)

Prilog sa skupa u časopisu | sažetak izlaganja sa skupa | međunarodna recenzija

Lacković, Zdravko Botulinum Toxin Type A and Rat Trigeminal Regions: The Search for Mechanism of Antinociceptive Action in Migraine and Other Headaches // Neurology. 2015

Podaci o odgovornosti

Lacković, Zdravko

engleski

Botulinum Toxin Type A and Rat Trigeminal Regions: The Search for Mechanism of Antinociceptive Action in Migraine and Other Headaches

OBJECTIVE:Meta-analyses suggest that botulinum toxin A (BoNT/A) is effective in treatment of chronic migraine, chronic daily headache, trigeminal neuralgia and medication overuse headache. Mechanism of action is unknown. It is usually assumed that antimigraine action is associated with BoNT/A enzymatic inactivation of SNAP25 and prevention of neurotransmitter release in the peripheral nerve endings. However, migraine is not a peripheral disease. Thus we investigated the BoNT/A action on dural neurogenic inflammation and pain in rat trigeminal region. BACKGROUND:Previously we demonstrated that the effect of BoNT/A on pain hypersensitivity in trigeminal region is dependent on toxin’s axonal transport in sensory neurons from periphery to CNS (Matak and Lackovic, Prog Neurobiol 119-120:2014 ; 39-59). Immunohistochemistry of BoNT/A protease activity (truncated SNAP25) was localized in sensory nuclei in capsaicin-sensitive afferent terminals (Matak at al., Pain 155: 2014 ; 1516-26). In different pain models BoNT/A reduced the neurogenic inflammation in dura mater which is believed to be associated with migraine pathophysiology (Filipovic at al., PLoS One 2012, 7: e29803. DESIGN/METHODS:Immunohistochemistry of BoNT/A protease activity (truncated SNAP25) and CGRP, assessment of pain in orofacial formalin test, measurement of pain supersensitivity by von Frey filaments in maxillofacial joint pain induced by Freund’s adjuvant, and assessment of neurogenic dural inflammation (extravasation) by Evans blue and histological examination. RESULTS:BoNT/A protease activity was present in dural nerves and colocalized with calcitonin gene related polypeptide (CGRP). Interestingly the toxin’s antinociceptive action in orofacial formalin test was prevented by opioid antagonist naltrexone. CONCLUSIONS:Antinociceptive activity of BoNT/A in trigeminal region might be associated with prevention of CGRP release from dural nerve endings but involves endogenous opioid system as well. Study Supported by: Croatian Ministry of Science, Education and Sport

botulinum toxin type A; pain; trigeminal region

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

nije evidentirano

Podaci o prilogu

2015.

nije evidentirano

objavljeno

Podaci o matičnoj publikaciji

Neurology

0028-3878

Podaci o skupu

67th American Academy of Neurology Annual Meeting

predavanje

18.04.2015-25.04.2015

Sjedinjene Američke Države

Povezanost rada

nije evidentirano

Indeksiranost